Form 4: Baxter International EVP Rosenbloom Reports Acquisition and Disposal of Shares

David S. Rosenbloom, EVP and General Counsel of Baxter International, reports the acquisition of 53,584 shares and disposal of 108,989 shares of common stock on March 6, 2024, following the grant of restricted stock units.

Summary

• On March 6, 2024, David S. Rosenbloom, EVP and General Counsel of Baxter International Inc., reported changes in beneficial ownership of the company's stock.
• Rosenbloom acquired 53,584 shares of common stock at $0 and disposed of 108,989 shares.
• Following these transactions, Rosenbloom beneficially owns 108,989 shares of Baxter International Inc.
• The acquisition was related to an annual equity grant consisting of restricted stock units (RSUs) that vest in three equal annual installments starting March 6, 2025.
• Rosenbloom has granted power of attorney to David S. Rosenbloom, Ellen K. Bradford, and Kimberly Olson to execute and file Forms 4, 5, and 144 on his behalf.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and regulatory compliance, indicating a neutral to slightly positive sentiment due to alignment of executive interests with shareholders.

Positives

• The grant of restricted stock units to the EVP and General Counsel aligns his interests with the long-term performance of the company.

Future Outlook

The restricted stock units are scheduled to vest in three equal annual installments beginning on March 6, 2025, subject to continued employment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the alignment of management's interests with shareholders.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in publicly traded companies like Baxter International.
• Companies such as Johnson & Johnson, Medtronic, and Abbott Laboratories also utilize restricted stock units and stock options to incentivize their executives.
• The vesting schedule of three years is a typical vesting period for RSUs in the healthcare industry.
• The reporting requirements under Section 16(a) of the Securities Exchange Act are consistently followed by executives across the industry to ensure transparency and compliance.

Stakeholder Impact

• Shareholders can view this as a positive sign that executive compensation is tied to the company's performance.
• Employees may see this as a standard practice for executive compensation within the company.

Key Dates